what is tirzepatide glp 1 FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Tirzepatide (GLP-1 / GIP)

Conclusion (Summary first) GLP-1 receptor agonists may increase the risk of cholelithiasis and gallbladder disease The risk is tending to be higher with drugs and dosages that cause greater weight loss The mechanism is reduced gallbladder motility + rapid weight loss Cholelithiasis risk: Overall picture In large-scale meta-analyses, GLP-1 receptor agonist use Gallbladder disease risk: RR 1.37 Cholelithiasis: RR 1.27 Cholecystitis: RR 1.36 1) It is important to note that while this is a significant increase, the "absolute risk is not high." Differences in risk by drug Liraglutide (Victoza) The increase in cholelithiasis risk is relatively clear In the SCALE trials, Gallstone-related events: 2.3% vs 1.0% (placebo) 2) Increased in the group with greater weight loss Semaglutide (Ozempic/Wegovy) In the STEP trials, etc., Gallbladder disease increasing trend (approx

Hyperglycemia impairs proteasome function by methylglyoxal

Use a cane to reduce pain from hip, knee, ankle, or foot arthritis

Fatigue affects a significant percentage of users, particularly in the early weeks

L-Carnitine is a naturally occurring amino acid-like compound produced in the body from lysine and methionine

Say hello to healthier-looking skin, as this supercharged serum targets visible signs of ageing